The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study

BJU International

Volumn 107, Issue 9, 2011, Pages 1426-1431

  Montorsi, Francesco ^a   Roehrborn, Claus ^b   Garcia Penit, Javier ^c   Borre, Michael ^d   Roeleveld, Ton A ^e   Alimi, Jean Charles ^f   Gagnier, Paul ^g   Wilson, Timothy H ^g  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c HOSPITAL COSTA DEL SOL   (Spain)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Medical Centre Alkmaar   (Netherlands)

^f Clinique Sainte Marguerite   (France)

^g GLAXOSMITHKLINE   (United States)

Author keywords

benign prostatic hyperplasia; CombAT; combined therapy; dutasteride; tamsulosin; urinary symptoms

Indexed keywords

DUTASTERIDE; DUTASTERIDE PLUS TAMSULOSIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MONOTHERAPY; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; URINE FLOW RATE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; AZASTEROIDS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATIC HYPERPLASIA; PROSTATISM; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79955471453     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10129.x     Document Type: Article

References (22)

1. Abrams P, Cardozo L, Fall M, et al,. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49 (Pubitemid 36151708)
2. Roehrborn CG,. Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. Rev Urol 2005; 7 (Suppl 8): S43-51.
3. Rosenberg MT, Staskin DR, Kaplan SA MacDiarmid SA, Newman DK, Ohl DA,. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61: 1535-46 (Pubitemid 47228616)
4. Mirone V, Imbimbo C, Longo N, Fusco F,. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol 2007; 51: 57-66 (Pubitemid 44821527)
5. Irwin DE, Milsom I, Hunksaar S, et al,. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15 (Pubitemid 44692945)
6. Sexton CC, Coyne KS, Kopp ZS, et al,. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 12-23
7. Häkkinen JT, Hakama M, Huhtala H, et al,. Impact of LUTS using bother index in Dan-PSS-1 questionnaire. Eur Urol 2007; 51: 473-8 (Pubitemid 44937781)
8. Abrams P, Andersson KE,. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006 (Pubitemid 47537675)
9. Malloy BJ, Price DT, Price RR, et al,. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998; 160: 937-43 (Pubitemid 29479558)
10. Nitti VW,. Is there a role for alpha-blockers for the treatment of voiding dysfunction unrelated to benign prostatic hyperplasia? Rev Urol 2005; 7 (Suppl 4): S49-55
11. Garg G, Singh D, Saraf S, Saraf S,. Management of benign prostate hyperplasia: an overview of alpha-adrenergic antagonist. Biol Pharm Bull 2006; 29: 1554-8. (Pubitemid 44166350)
12. Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S,. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-53 (Pubitemid 47036593)
13. Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gõmez JM, Castro R,. Benign prostatic hyperplasia as a progressive disease: a guide to risk factors and options for medical management. Int J Clin Pract 2008; 62: 1076-86 (Pubitemid 351793595)
14. Roehrborn CG, Van Kerrebroeck P, Nordling J,. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled trials. BJU Int 2003; 92: 257-61 (Pubitemid 36966589)
15. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ,. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547-54 (Pubitemid 39345720)
16. Roehrborn CG, Siami P, Barkin J, et al,. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-31
17. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
18. Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F,. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 2009; 12: 369-74
19. Siami P, Roehrborn CG, Barkin J, et al,. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: The CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28: 770-9 (Pubitemid 47499255)
20. Barry MJ, Williford WO, Fowler FJ Jr, Jones KM, Lepor H,. Filling and voiding symptoms in the American Urological Association symptom index: The value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. J Urol 2000; 164: 1559-64
21. Roehrborn CG,. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006; 9: 121-5 (Pubitemid 43970960)
22. Welch G, Kawachi I, Barry MJ, et al,. Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the Health Professionals Follow-up Study. Urology 1998; 51: 422-7 (Pubitemid 28136680)